Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
Article about the study:
“We did the work that the medical authorities failed to do, we conducted the most comprehensive review of the available data on ivermectin,” said Pierre Kory, MD, president and chief medical officer of the FLCCC. “We applied the gold standard to qualify the data reviewed before concluding that ivermectin can end this pandemic.”
A focus of the manuscript was on the 27 controlled trials available in January 2021, 15 of which were randomised controlled trials (RCT’s).
Consistent with numerous meta-analyses of ivermectin RCT’s since published by expert panels from the UK, Italy, Spain and Japan, they found a large, statistically significant reduction in mortality, time to recovery, and viral clearance in COVID-19 patients treated with ivermectin.
“Our latest research shows, once again, that when the totality of the evidence is examined, there is no doubt that ivermectin is highly effective as a safe prophylaxis and treatment for COVID-19,” said Paul E. Marik, founding member of the FLCCC and Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.Immediate Use of Ivermectin Medicine Globally Can End COVID-19 Pandemic: Scientists